Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.69 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATF4 | P18848 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458531 | 0.86 | FAAH (0.58) | FAAHHRH2HRH1GAAALDH1A1 | |
| SCHEMBL5451937 | 0.82 | FAAH (1.00) | FAAHALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL5212355 | 0.80 | TEAD1 (0.54) | HRH2HRH1ALDH1A1MEN1LMNA | |
| SCHEMBL5447729 | 0.80 | FAAH (0.88) | FAAHGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2178051 | 0.80 | HRH2 (0.62) | FAAHHRH2HRH1GAAALDH1A1 | |
| SCHEMBL14627810 | 0.79 | FAAH (0.79) | FAAHALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL2177380 | 0.79 | HRH2 (0.71) | FAAHHRH2HRH1 | |
| SCHEMBL2463086 | 0.79 | FAAH (0.52) | FAAHHRH2HRH1ALDH1A1CHEK2 | |
| SCHEMBL4322579 | 0.78 | GPR119 (0.65) | FAAHALDH1A1MEN1LMNAHPGD | |
| SCHEMBL5447756 | 0.77 | FAAH (0.66) | FAAHGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674805-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | claimed |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | claimed |
| EP-1708994-B1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-08-08 | — | — | EP | claimed |
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-7674805-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-7674805-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | disclosed |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | disclosed |
| US-7439257-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-21 | — | — | US | disclosed |
| US-7439257-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-21 | — | — | US | disclosed |
| US-7439257-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1708994-B1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | FAAH 470/4885HRH2 1691/4885HRH1 1675/4885 |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | FAAH 470/4885HRH2 1691/4885HRH1 1675/4885 |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | FAAH 470/4885HRH2 1691/4885HRH1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.